

Supplementary Table S1. Coronavirus disease 2019 severity in patients with SLE by antimalarial use

	All SLE (n=80)	Antimalarial Yes (n=51)	Antimalarial No (n=29)
Hospitalized	45 (56%)	29 (57%)	16 (55%)
Level of Care*			
Did not require supplemental oxygen	48 (60%)	33 (65%)	15 (52%)
Required supplemental oxygen, non-invasive or invasive ventilation or ECMO	30 (38%)	17 (33%)	13 (45%)

*Information unknown for 2 cases

References (continued)

- 7 Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing. The White House. <https://www.whitehouse.gov/briefings-statements/remarks-president-trump-vice-president-pence-members-coronavirus-task-force-press-briefing-19/> (accessed 24 Apr 2020).
- 8 Monti S, Montecucco C. Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit. *Ann Rheum Dis* 2020;;annrheumdis-2020-217524. doi:10.1136/annrheumdis-2020-217524
- 9 Gianfrancesco MA, Hyrich KL, Gossec L, *et al.* Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. *The Lancet Rheumatology* 2020;;S2665991320300953. doi:10.1016/S2665-9913(20)30095-3
- 10 Mathian A, Mahevas M, Rohmer J, *et al.* Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. *Annals of the Rheumatic Diseases* Published Online First: 24 April 2020. doi:10.1136/annrheumdis-2020-217566
- 11 Search of: Recruiting, Completed Studies | COVID | Hydroxychloroquine - List Results - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=COVID&intr=Hydroxychloroquine&Search=Apply&rcrs=a&recrs=e&age_v=&gndr=&type=&rslt= (accessed 19 Apr 2020).
- 12 Dyllal J, Gross R, Kindrachuk J, *et al.* Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies. *Drugs* 2017;;77:1935–66. doi:10.1007/s40265-017-0830-1
- 13 Dyllal J, Coleman CM, Hart BJ, *et al.* Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. *Antimicrob Agents Chemother* 2014;;58:4885–93. doi:10.1128/AAC.03036-14
- 14 Yao X, Ye F, Zhang M, *et al.* In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* Published Online First: 9 March 2020. doi:10.1093/cid/ciaa237
- 15 Liu J, Cao R, Xu M, *et al.* Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 2020;;6:16. doi:10.1038/s41421-020-0156-0
- 16 Tuntland T, Ethell B, Kosaka T, *et al.* Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. *Front Pharmacol* 2014;;5:174. doi:10.3389/fphar.2014.00174

- 17 Barnard DL, Day CW, Bailey K, *et al.* Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. *Antivir Chem Chemother* 2006;**17**:275–84. doi:10.1177/095632020601700505
- 18 CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER:021246Orig1s045 and 021087Orig1s062 [Abstracted from NDA 21087/S-062 Clinical Review, T. Vargas-Kasambira]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/021246Orig1s045_021087Orig1s062SumR.pdf (accessed 19 Apr 2020).
- 19 Rayner CR, Bulik CC, Kamal MA, *et al.* Pharmacokinetic-Pharmacodynamic Determinants of Oseltamivir Efficacy Using Data from Phase 2 Inoculation Studies. *Antimicrobial Agents and Chemotherapy* Published Online First: 9 May 2013. doi:10.1128/AAC.02440-12
- 20 Arnold SL, Buckner F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. *Clin Transl Sci* Published Online First: 8 April 2020. doi:10.1111/cts.12797
- 21 Petri M, Elkhailifa M, Li J, *et al.* Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. *Arthritis Rheumatol* 2019;:art.41121. doi:10.1002/art.41121
- 22 Tang W, Cao Z, Han M, *et al.* Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. *Infectious Diseases (except HIV/AIDS)* 2020. doi:10.1101/2020.04.10.20060558